Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: Learning from a clinical case

ESMO Open

Volumn 3, Issue 1, 2018, Pages

  Martinelli, Erika ^a   Troiani, Teresa ^a   Sforza, Vincenzo ^a   Martini, Giulia ^a   Cardone, Claudia ^a   Vitiello, Pietro Paolo ^a   Ciardiello, Davide ^a   Rachiglio, Anna Maria ^b   Normanno, Nicola ^b   Sartore Bianchi, Andrea ^c,d   Marsoni, Silvia ^e   Bardelli, Alberto ^f   Siena, Salvatore ^c,d   Ciardiello, Fortunato ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c Niguarda Cancer Center   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e CANDIOLO CANCER INSTITUTE   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

Author keywords

colorectal cancer; her2 gene amplification; her2 inhibitors; next generation sequencing

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FOLINIC ACID; LAPATINIB; OXALIPLATIN; PERTUZUMAB; RAS PROTEIN; REGORAFENIB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CASE REPORT; CLINICAL ARTICLE; COLON ADENOCARCINOMA; COLONOSCOPY; DRUG EFFICACY; DYSPNEA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; HEMICOLECTOMY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NEXT GENERATION SEQUENCING; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; WILD TYPE;

EID: 85047647967     PISSN: None     EISSN: 20597029     Source Type: Journal    
DOI: 10.1136/esmoopen-2017-000299     Document Type: Article

References (18)

1. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016;27:1386-422.
2. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-54.
3. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160-74.
4. Sforza V, Martinelli E, Ciardiello F, et al. Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World J Gastroenterol 2016;22:6345-61.
5. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012;483:100-3.
6. Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011;1:508-23.
7. Yonesaka K, Zejnullahu K, Okamoto I, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011;3:99ra86.
8. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-7.
9. Kavuri SM, Jain N, Galimi F, et al. HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov 2015;5:832-41.
10. Clark JW, Hollis D, Mayer R, et al. Phase II trial of 5-fluorouracil (5-FU), leucovorin (LV), oxaliplatin (Ox), and trastuzumab (T) for patients with metastatic colorectal cancer (CRC) refractory to initial therapy. Onkologie 2003;26(Suppl 3):13-46.
11. Ramanathan RK, Hwang JJ, Zamboni WC, et al. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest 2004;22:858-65.
12. Valtorta E, Martino C, Sartore-Bianchi A, et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol 2015;28:1481-91.
13. Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016;17:738-46.
14. Hurwitz H, Hainsworth JD, Swanton C, et al. Targeted therapy for gastrointestinaI (GI) tumors based on molecular profiles: early results from MyPathway, an open-label phase IIa basket study in patients with advanced solid. J Clin Oncol 2016;34(Suppl 4S).
15. Normanno N, Rachiglio AM, Lambiase M, et al. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial. Ann Oncol 2015;26:1710-4.
16. Ciardiello F, Normanno N, Maiello E, et al. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by nextgeneration sequencing: findings from the CAPRI-GOIM trial. Ann Oncol 2014;25:1756-61.
17. Martinelli E, Sforza V, Cardone C, et al. Clinical outcome and molecular characterization of chemorefractory metastatic colorectal cancer patients with long term efficacy of regorafenib treatment. ESMO Open. doi: 10.1136/esmoopen-2017-000177. [Epub ahead of print 29 Jul 2017].
18. Schalper KA, Velcheti V, Carvajal D, et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res 2014;20:2773-82.